US Edition
Pfizer Raises Annual Profit Forecast
UNITED STATES, AUG 5 – Pfizer raised its 2025 profit forecast due to strong sales of key drugs Vyndaqel and Eliquis and expects $7.7 billion in cost savings by 2027, company said.
- On Tuesday, Pfizer hiked its full-year adjusted profit guidance to $2.90 to $3.10 per share, up from $2.80 to $3, citing cost cuts and strong results.
- Amid looming patent expiries, Pfizer expanded its cost-cutting efforts in April to recover from Covid business decline and stock price drop.
- During Q2, Pfizer's revenue reached $14.65 billion, up 10%, and adjusted earnings per share were $0.78, surpassing expectations.
- Shares of Pfizer rose more than 4% on Tuesday as it maintained its 2025 revenue forecast of $61 billion to $64 billion.
- Guidance accounts for tariffs from China, Canada and Mexico and potential price changes based on a letter received last week, with Pfizer targeting $7.2bn in net savings by 2027.
Insights by Ground AI
Does this summary seem wrong?
11 Articles
11 Articles
Pfizer Q2 Results: Pharma major's sales jump to $14.65 billion; firm raises profit forecast for 2025 over cost cuts
Pfizer Q2 Results: Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised its profit forecast for 2025 over cost cuts.
·New Delhi, India
Read Full Article
Coverage Details
Total News Sources11
Leaning Left3Leaning Right0Center4Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 43%
C 57%
Factuality
To view factuality data please Upgrade to Premium
